Alnylam Pharmaceuticals (ALNY) stock surged 5.28% during intraday trading on Tuesday, reflecting strong positive sentiment from investors.
The significant price movement appears to be driven by multiple analyst firms maintaining bullish ratings on the company. Both Canaccord Genuity and Barclays issued reports today reaffirming their Buy ratings on Alnylam Pharma, with price targets of $429.00 and $527.00 respectively.
These positive analyst actions, highlighting confidence in the company's prospects, likely contributed to the stock's upward momentum during the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.